Last reviewed · How we verify
VEE Vaccine
VEE Vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 2 development. Also known as: TC-83.
The VEE Vaccine is a vaccine component that induces an immune response, used to prevent Venezuelan Equine Encephalomyelitis Virus Disease and other related conditions such as Venezuelan Equine Encephalitis Virus Infection, Venezuelan Equine Encephalitis, Western Equine Encephalitis, and Eastern Equine Encephalitis. It is a type of biological vaccine, classified as a vaccine component with a modality of inducing an immune response.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VEE Vaccine |
|---|---|
| Also known as | TC-83 |
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers (PHASE1)
- Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults (PHASE1)
- Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection (PHASE1)
- VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults (PHASE1)
- Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine (PHASE1)
- Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults (PHASE2)
- Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults (PHASE2)
- Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VEE Vaccine CI brief — competitive landscape report
- VEE Vaccine updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI
Frequently asked questions about VEE Vaccine
What is VEE Vaccine?
Who makes VEE Vaccine?
Is VEE Vaccine also known as anything else?
What development phase is VEE Vaccine in?
Related
- Manufacturer: U.S. Army Medical Research and Development Command — full pipeline
- Also known as: TC-83
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing